CD8A and neoplasm: In contrast to this, tumor specimens from men with intermediate- to high-risk PCa pretreated with abiraterone acetate prior to radical prostatectomy yielded less CD8+ T cells and a trend for decreased PD-L1 positivity (7% vs. 21%; p = 0.062), compared to untreated PCas [35].